Speaker Profile
M.D., Director/CMO of Oncology, UnitedHealthcare
Biography
Lucy R. Langer, MD, MSHS, is the National Medical Director/CMO of Oncology,
Genomics, and Laboratory at UnitedHealthcare.
Dr. Langer earned her medical degree at Stanford and completed her fellowship in
hematology and oncology, with a master’s degree in Health Services Research at the UCLA
. She has been a practicing oncologist with Compass
Oncology in Portland, OR since 2007, focused primarily on breast cancer.
Dr. Langer is known in the field of oncology not only for her leadership as two-term Chair of
the US Oncology National Policy Board Executive Committee, but also for her work in
creating and leading the National US Oncology Genetic Risk Evaluation and Testing
(GREAT) Program. She served as Practice President of Compass Oncology for eight years,
overseeing the development of a $40M Cancer Center and the expansion of the APP and
social worker programs to better meet patient needs and enhance care delivery.
At UnitedHealthcare, Lucy is passionate about working to ensure our members receive high
quality care, while keeping it affordable and accessible.
Dr. Langer is a member of several professional organizations, including the American
Society of Clinical Oncology (ASCO), the American Association of Cancer Research
(AACR), the Oregon Society of Medical Oncology (OSMO), and the American Society of
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Adrian Lee, UPMC
PMWC Award Ceremony
• Dennis J. Slamon, UCLA
• Arul M. Chinnaiyan, University of Michigan
Keynote: Molecular Diversity of Human Malignancies: Diagnostic and Therapeutic Implications
• Dennis J. Slamon, UCLA
Keynote: From Cancer Drivers to Clinical Decisions: Transforming Tumor Genomics
• Arul M. Chinnaiyan, University of Michigan
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Adrian Lee, UPMC
• Pedram Razavi, MSK
• Minetta Liu, Natera
• Emre Baser, Astrazeneca
• Christian Rolfo, Ohio State
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, UPenn
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
• C. Ola Landgren, U Miami
• Christopher Lieu, U Colorado
Rapid MRD to Treatment Decisions: Standardized ctDNA at Scale
• Chair: Luca Quagliata, Thermo Fisher
• Christian Rolfo, Ohio State
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• Chair: David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
• Daniel De Carvalho, University of Toronto
From Detection to Direction: Whole-Genome MRD for Therapy Guidance at Scale
• Phil Febbo, Veracyte
Precision Engineering: Customizing High-Sensitivity ctDNA Assays for Therapy Guidance at Scale
• Siyuan Chen, Twist Bioscience
From Validation to Payment: Coverage Pathways That Work
• Chair: Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society (ACS)
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
